All In Biotech

Drug Trial Radar · NCT07636772

A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma

A Phase II Clinical Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Anti-tumor Efficacy of AK146D1 Monotherapy or Combined With AK112 in Patients With Advanced Urothelial Carcinoma

Last checked: Nov 19, 2026Latest source record: Jun 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

132

Planned (sponsor's estimate)

Start

Jun 22, 2026

Primary completion

Aug 24, 2028

Study completion Aug 24, 2028

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Jun 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II clinical study aimed at evaluating the safety, tolerability, antitumor efficacy, PK and immunogenicity of AK146D1 monotherapy or combined with AK112 in advanced Urothelial carcinoma.

Conditions

  • Urothelial Carcinoma (UC)

Interventions

  • AK146D1 for injectionDrug

    AK146D1 for injection is an antiTrop2/Nectin4 bispecific antibody-drug conjugate

  • AK112 InjectionDrug

    AK112 Injection is a PD-1/VEGF bispecific antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with dose limiting toxicities(DLTs)Time frame: During the first 3 weeks of treatment
  2. Objective Response Rate(ORR)Time frame: Up to 2 years
  3. Number of participants with adverse events (AEs)Time frame: From the time of informed consent signed through 90 days after the last dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.